The Board of Directors

Robin Beaumont Dip. App. Chem., MBA
Independent
Non-executive Chairman

Robin Beaumont joined Arana’s board in August 2007 and was appointed Chairman on 1 November 2007.

Robin was Managing Director of the Advent Venture Capital group until 1998 and represented Advent’s interests as a director of five investee companies, including Primary Health Care Limited and the Ayers Rock Resort Company. Prior to joining Advent, he had more than 10 years of strategy consulting experience, after holding senior management positions in the Pacific Dunlop group. He is currently the Chairman of Select Vaccines Limited (director since 2005) and was Chairman of the Cooperative Research Centre for Diagnostics until June 2007.Robin was a Non-executive Director of EvoGenix Limited until its merger with Peptech Limited (the previous name of Arana Therapeutics Limited).

During the last three years he has also served as a director of listed companies: Gropep Limited (1999 to 2006) and EvoGenix Limited (2004 to August 2007).

He is a member of the Remuneration Committee and Audit and Compliance Committee.

Gordon Black BSc, MBA
Non-independent
Non-executive Director

Gordon Black joined Arana’s board in October 2008. Gordon is actively involved in the development of the Australian life sciences industry. He is currently Managing Director and co-founder of BioFusion Capital (a significant shareholder in Arana), a specialist life sciences venture capital fund and early stage investor in EvoGenix Limited. Gordon also co-founded East West Capital Limited in 2005, a specialist funds management company, investing in Australian listed equities for Australian and international investors.

Previously, Gordon worked in the U.S. and Asia Pacific with Merrill Lynch, New York in capital markets and with Du Pont in the global chemical industry in the U.S. head office Wilmington, Delaware, as Senior Analyst Special Projects and later in Corporate Planning supporting the Du Pont global business units operating in the Asia Pacific region.

After returning to Sydney in 1994, Gordon joined the ASX listed property investment company Ipoh Limited. As Director - Corporate Services, he reported to the Managing Director and was responsible for strategic planning, capital raising and investment prior to the company being acquired by the Government Investment Corporation of Singapore in 2001.

Lincoln Chee MBBS, FRCS, FAMS, FAAO-HNS
Non-independent
Non-executive Director

Lincoln Chee joined Arana’s board in April 2007. He brings to the board more than 18 years of healthcare experience. During his career he has been a consultant surgeon with Singapore General Hospital and a clinical lecturer at the National University of Singapore.

He is currently Chief Executive of Quality HealthCare Asia Limited, Hong Kong’s leading healthcare group listed on the Hong Kong Stock Exchange (director since March 2003).

Dr Chee is also a member of the Health Taskforce Business Professional Federation of Hong Kong and member of the Government of HKSAR Health and Welfare steering committee on electronic medical records.

Chris Harris B.Ec, FCPA, FAICD
Independent
Non-executive Director

Chris Harris joined Arana’s board in August 2007. Chris is a former Group Managing Director and Chief Executive Officer of pharmaceutical company F.H. Faulding & Co. Limited. His earlier roles with the same company were as Finance Director and Chief Operating Officer. Since leaving Faulding in 1993, he has had a distinguished record of leadership as a director and chair of many major Australian companies. Chris is currently Chair of Argo Investments Limited (director since 1994), and Non-executive Director of Australian Vintage Limited (director since 1994), Adelaide Brighton Limited (director since 1995) and JM Financial Group Limited (director since 1999).

Chris was formerly the Non-executive Chairman of EvoGenix Limited (2004 to August 2007) until its merger with Peptech Limited (the previous name of Arana Therapeutics Limited).

He is Chairman of the Audit and Compliance Committee and a member of the Remuneration Committee.

George Jessup MBBS, MBiomed Eng MBA
Non-independent
Non-executive Director

George joined Arana’s board in November 2007. George is active in investing in and providing strategic direction to biotechnology companies. He is co-founder and Managing Director of Start-up Australia, which manages institutional funds and invests in life science companies. Start-up Australia has played a key role in assisting numerous companies move from start-up to becoming significant players in their market, achieving an initial public offering or mergers and acquisitions. These companies now have operations in Australia, North America, China, India and South Africa. George has extensive experience in senior management roles in the medical device and pharmaceutical industries in the U.S. and Australia, including an appointment in the U.S. as Global Director of Medical Affairs of the Medical Device Division of an international pharmaceutical company (American Cyanamid Company, later acquired by Wyeth).

George was formerly Non-executive Director of EvoGenix Limited (2001 to August 2007) until its merger with Peptech Limited (the previous name of Arana Therapeutics Limited) and was a Non-executive Director of Bionomics Limited (2005 to April 2008).

He is Chairman of the Remuneration Committee and a member of the Audit and Compliance Committee.